If your goal is fewer side effects, the documented path is slower titration on FDA-approved tirzepatide, not compounded sub-therapeutic dosing
However, eligibility is also extended to individuals with a lower BMI of 27 or greater if they have at least one weight-related health condition
The model-based analysis suggested that drug product strength influences the rate of absorption but not the bioavailability (Table 4), indicating that the total exposure of semaglutide is not affected by the product strength
Ann Intern Med 88(2):168175 Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX, Ferrans VJ (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin
In 2020, the FDA OKd it for cutting cardiovascular risk in people with diabetes and heart disease